Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Jingjing Li"'
Autor:
Jie Ji, Yan Li, Jiao Feng, Yingqun Zhou, Qiang Yu, Jianye Wu, Weiqi Dai, Liwei Wu, Yuanyuan Zheng, Chuanyong Guo, Jingjing Li
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-16 (2021)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Primary liver cancer (PLC) is a common malignancy with high morbidity and mortality. Poor prognosis and easy recurrence on PLC patients calls for optimizations of the current conventional treatments and the exploration of novel therapeutic strategies
Autor:
Yang Liu, Zheng Chen, Wu Xianrui, Zhi zhao Chen, Feng-Jie Tang, Jun lin Liao, Jianda Zhou, Ke Cao, Jingjing Li, Zi zi Chen, Xiang Chen
Publikováno v:
Journal of Cellular and Molecular Medicine
Cutaneous melanoma (CM) is an aggressive cancer; given that initial and specific signs are lacking, diagnosis is often late and the prognosis is poor. RNA modification has been widely studied in tumour progression. Nevertheless, little progress has b
Publikováno v:
Journal of Surgical Oncology. 123:1708-1715
OBJECTIVE This study aimed to investigate alterations in pre- and post-neoadjuvant chemotherapy (NACT) tumor-infiltrating immune cells and subsequent evaluation of the predictive and prognostic value of these changes in gastric cancer (GC). METHODS F
Autor:
Yuanyuan Ma, Sixue Liu, Shaolei Li, Zhenyu Hu, Jingjing Li, Dafei Wu, Xing Wang, Nan Wu, Hongwei Duan, Xiang Li, Yaqi Wang, Shi Yan, Xuemei Lu
Publikováno v:
Transl Lung Cancer Res
Background The concept of multi-step progression from atypical adenomatous hyperplasia (AAH) to invasive adenocarcinoma (ADC) has been proposed, and ground-glass nodules (GGNs) may play a critical role during the early lung tumorigenesis. We present
Autor:
Paola Ulivi, Jingjing Li, Chunhe Yan, Eric H. Bernicker, Bin Zhang, Yu Zhang, Anthonie J. van der Wekken, Vincent Thomas de Montpréville, Zhenfa Zhang, Dongsheng Yue, Changli Wang, Petros Christopoulos, Feng Xu, Marc G. Denis, Lin Shao
Publikováno v:
Translational lung cancer research, 10(3), 1525-1535. AME PUBL CO
Background: In non-small cell lung cancer (NSCLC), anaplastic lymphoma kinase (ALK) rearrangement characterizes a subgroup of patients who show sensitivity to ALK tyrosine kinase inhibitors (TKIs). However, the prognoses of these patients are heterog
Autor:
Yu Liang, Yuhua Shan, Chenjie Xie, Jingjing Li, Lei Zhang, Hongxiang Gao, Song Gu, Jing Wang, Ruicheng Tian, Min Xu
Publikováno v:
World Journal of Clinical Cases
BACKGROUND Inflammatory myofibroblastic tumor (IMT) is a distinct tumor with a low incidence rate, which can be diagnosed at any age with a predilection for children and adolescents. Although IMT is visible in any tissues and organs, it is more commo
Publikováno v:
Translational Cancer Research
Background The role of long non-coding RNA growth arrest-specific 5 (GAS5) in cancer development is controversial. The aim of this study was to evaluate the prognostic significance of GAS5 in kidney renal clear cell carcinoma (KIRC) and liver hepatoc
Publikováno v:
Translational Cancer Research
Background Nivolumab and pembrolizumab were approved as immune checkpoint inhibitors for third-line treatment of advanced gastric or esophagogastric junction cancer (GC/EGJC) in 2017. However, immunotherapy monotherapy has low efficacy. Apatinib has
Publikováno v:
Cancer Management and Research. 12:7009-7019
Background This retrospective study evaluated the prognostic significance of hemoglobin (Hb) levels in patients (pts) with unresectable locally advanced or metastatic gastric cancer who have not previously received chemotherapy. Patients and Methods
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-19 (2020)
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research : CR
Liver cancer has become the sixth most diagnosed cancer and the fourth leading cause of cancer death worldwide. Hepatocellular carcinoma (HCC) is responsible for up to 75–85% of primary liver cancers, and sorafenib is the first targeted drug for ad